Dr. Lal PathLabs strengthens its genomics capabilities with Illumina's NovaSeq X Series
The NovaSeq X system features Illumina's cutting-edge XLEAP-SBS chemistry, offering unmatched throughput, accuracy, and sustainability
The NovaSeq X system features Illumina's cutting-edge XLEAP-SBS chemistry, offering unmatched throughput, accuracy, and sustainability
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
The project will be instrumental in enhancing the company's API manufacturing capacity and global reach
This strategic expansion marks a significant step in the company's global growth strategy
AMPLIFY Phase III trial results demonstrated statistically significant and clinically meaningful improvement in progression-free survival for Calquence combinations
The approval is for the generic version of Victoza, indicated for the treatment of insufficiently controlled Type 2 Diabetes Mellitus
Operating income on consolidated basis increased by 38.10% at Rs 44.58 crore in Q4 FY25
The company also announced results for the third quarter, reporting sales at Rs. 992 crore, flat versus year ago
Subscribe To Our Newsletter & Stay Updated